NFE2L2 and chronic obstructive pulmonary disease: Furthermore, the genes NQO1, HO1, superoxide dismutase type 1 (SOD1), and thioredoxin reductase 1 (TXNRD1) were downregulated in COPD patients, with increased expression following treatment with Nrf2 activators [198].